Prostatic Hyperplasia

• 

  Subject Areas on Research

  • A coaxial microwave applicator for transurethral hyperthermia of the prostate. 
  • A new look at bladder neck obstruction by the food and drug administration regulators: guide lines for investigation of benign prostatic hypertrophy. 
  • A transgenic mouse prostate cancer model. 
  • ACR Appropriateness Criteria® Lower Urinary Tract Symptoms-Suspicion of Benign Prostatic Hyperplasia. 
  • Accurate determination of prostate size via digital rectal examination and transrectal ultrasound. 
  • Acute urinary retention associated with prostatic carcinoma. 
  • Alpha1-adrenergic blockers and intraoperative floppy-iris syndrome. 
  • Analysis of urinary function using validated instruments and uroflowmetry after primary and salvage prostate cryoablation. 
  • Aspiration biopsy of prostate. 
  • Association of Treatment With 5α-Reductase Inhibitors and Prostate Cancer Mortality Among Older Adults. 
  • Baseline prostate inflammation is associated with a reduced risk of prostate cancer in men undergoing repeat prostate biopsy: results from the REDUCE study. 
  • Benign prostatic hyperplasia. New concepts in the 1990s. 
  • Benign prostatic hyperplasia: diagnosis and treatment. Benign Prostatic Hyperplasia Guideline Panel. Agency for Health Care Policy and Research. 
  • Benign prostatic hypertrophy and uterine leiomyomas: analogous or dissimilar diseases? 
  • Blue Vision (Cyanopsia) Associated With TURP Syndrome: A Case Report. 
  • CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. 
  • Comparison of lower urinary tract symptom severity and associated bother between community-dwelling black and white men: the Olmsted County Study of Urinary Symptoms and Health Status and the Flint Men's Health Study. 
  • Detection of human papillomavirus in the prostate by polymerase chain reaction and in situ hybridization. 
  • Differential immunoreactivity of epidermal growth factor receptor in benign, dysplastic and malignant prostatic tissues. 
  • Differential immunoreactivity of her-2/neu oncoprotein in prostatic tissues. 
  • Differential immunoreactivity of transforming growth factor alpha in benign, dysplastic and malignant prostatic tissues. 
  • Diseases of the prostate. 
  • Does Peak Urine Flow Rate Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from REDUCE. 
  • Does Prostate Size Predict the Development of Incident Lower Urinary Tract Symptoms in Men with Mild to No Current Symptoms? Results from the REDUCE Trial. 
  • Does prior surgical interventional therapy for BPH affect the oncological or functional outcomes after primary whole-gland prostate cryoablation for localized prostate cancer? 
  • Duodenal glucagonoma: a case report. 
  • E-cadherin is downregulated in benign prostatic hyperplasia and required for tight junction formation and permeability barrier in the prostatic epithelial cell monolayer. 
  • Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. 
  • Evaluation of diagnostic imaging technologies and therapeutics devices: better information for better decisions: proceedings of a multidisciplinary workshop. 
  • Expression of p14ARF, p15INK4b, p16INK4a, and DCR2 increases during prostate cancer progression. 
  • Geographic variations in the use of medical and surgical therapies for benign prostatic hyperplasia. 
  • Identification, quantification, and localization of mRNA for three distinct alpha 1 adrenergic receptor subtypes in human prostate. 
  • In vitro and in vivo evaluation of dihydropyrimidinone C-5 amides as potent and selective alpha(1A) receptor antagonists for the treatment of benign prostatic hyperplasia. 
  • In vitro cultivation of prostatic epithelium. 
  • Inferior vena cava compression due to massive hydronephrosis from bladder outlet obstruction. 
  • Influence of E. coli-induced prostatic inflammation on expression of androgen-responsive genes and transforming growth factor beta 1 cascade genes in rats. 
  • Insulin-like growth factor-1, insulin-like growth factor binding protein-3, and body mass index: clinical correlates of prostate volume among Black men. 
  • Lifestyle and lower urinary tract symptoms: what is the correlation in men? 
  • Long-term testosterone gel (AndroGel) treatment maintains beneficial effects on sexual function and mood, lean and fat mass, and bone mineral density in hypogonadal men. 
  • Longitudinal changes in lower urinary tract symptoms among a cohort of black American men: the Flint Men's Health Study. 
  • Loss of uteroglobin expression in prostate cancer: relationship to advancing grade. 
  • Measuring costs in multisite randomized controlled trials: lessons from the VA Cooperative Studies Program. 
  • Microwave thermotherapy for benign prostatic hyperplasia with the Dornier Urowave: results of a randomized, double-blind, multicenter, sham-controlled trial. 
  • Molecular correlates in urine for the obesity and prostatic inflammation of BPH/LUTS patients. 
  • Monoclonal antibodies to different epitopes on a prostate tumor-associated antigen. Implications for immunotherapy. 
  • Morphologic and immunologic studies of human prostatic carcinoma. 
  • Obesity is associated with increased prostate growth and attenuated prostate volume reduction by dutasteride. 
  • Oncornavirus-like protein expression in human prostatic tissue. 
  • PSA predicts development of incident lower urinary tract symptoms: results from the REDUCE study. 
  • Panurethral stricture after photovaporization of the prostate for benign prostatic hyperplasia. 
  • Pentosan polysulfate decreases prostate smooth muscle proliferation and extracellular matrix turnover. 
  • Pilot study to explore effects of low-fat, flaxseed-supplemented diet on proliferation of benign prostatic epithelium and prostate-specific antigen. 
  • Potential selection bias in a community-based study of PSA levels in African-American men. 
  • Proceedings of the 99th meeting of the Food and Drug Administration Cardiovascular and Renal Drugs Advisory Committee. May 29th and 30th, 2003. 
  • Production of monoclonal antibody alpha Pro3 recognizing a human prostatic carcinoma antigen. 
  • Prostate cancer 1997--practicing what we preach. 
  • Prostate cancer early detection practices among men with a family history of disease. 
  • Prostate-specific antigen 1.5-4.0 ng/mL: a diagnostic challenge and danger zone. 
  • Prostate-specific antigen-enhanced testing and risk stratification for chemoprevention trials. 
  • Prostatic disorders: MR imaging at 1.5 T. 
  • Real-time quantitative RT-PCR assay of prostate-specific antigen and prostate-specific membrane antigen in peripheral blood for detection of prostate cancer micrometastasis. 
  • Reduction of human prostate tumor vascularity by the alpha1-adrenoceptor antagonist terazosin. 
  • Relationship of serum sex-steroid hormones and prostate volume in African American men. 
  • Results of a 5-year multicenter trial of a new generation cooled high energy transurethral microwave thermal therapy catheter for benign prostatic hyperplasia. 
  • Risk factors for delayed hematuria following photoselective vaporization of the prostate. 
  • Risk factors for lower urinary tract symptoms in a population-based sample of African-American men. 
  • Scanning and transmission electron microscopy of human prostatic acinar cells. 
  • Scanning electron microscopy of hyperplastic and neoplastic human prostate. 
  • Serum cholesterol and risk of lower urinary tract symptoms progression: Results from the Reduction by Dutasteride of Prostate Cancer Events study. 
  • Somatic single hits inactivate the X-linked tumor suppressor FOXP3 in the prostate. 
  • Tamsulosin and the intraoperative floppy iris syndrome. 
  • Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma. 
  • The alpha 1C-adrenoceptor in human prostate: cloning, functional expression, and localization to specific prostatic cell types. 
  • The effect of alpha1-adrenergic receptor antagonist tamsulosin (Flomax) on iris dilator smooth muscle anatomy. 
  • The natural history of lower urinary tract symptoms in black American men: relationships with aging, prostate size, flow rate and bothersomeness. 
  • Type IV collagenase (matrix metalloproteinase-2 and -9) in prostate cancer. 
  • Urine chemokines indicate pathogenic association of obesity with BPH/LUTS. 
  • Use of Structural Equation Modeling to Demonstrate the Differential Impact of Storage and Voiding Lower Urinary Tract Symptoms on Symptom Bother and Quality of Life during Treatment for Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia. 
• 

  Keywords of People

  • Preminger, Glenn Michael, James F. Glenn, M.D. Distinguished Professor of Urology, Surgery, Urology